QR code

Cardiotoxicity risk in metastatic castration-resistant prostate cancer: enzalutamide versus abiraterone

Abstract Background Chemotherapy-naïve patients with metastatic castration-resistant prostate cancer (mCRPC) treated with abiraterone (ABI) have a higher cardiovascular (CV) event-related hospitalization risk than those treated with enzalutamide (ENZA). This study aimed to assess CV event risk in ch...

Volledige beschrijving

Bewaard in:
Hoofdauteurs: Alan H. Bryce, David Nimke, Christopher Young, Qiujun Shao, Nigel Rozario, Pinal Kamdar, Jasmina Ivanova, Irene Varghese, Maelys Touya
Formaat: Artigo
Taal:Inglês
Gepubliceerd in: BMC 2026-03-01
Reeks:Cardio-Oncology
Onderwerpen:
Androgen-receptor pathway inhibitor
CV disease
CV events
Major adverse cardiac events
mCRPC
Online toegang:https://doi.org/10.1186/s40959-026-00465-3
Tags: Voeg label toe
Geen labels, Wees de eerste die dit record labelt!

Gelijkaardige items